PDCD1LG2 and breast cancer: In addition, PDL1, PDCD1LG2 (PDL2) and the stemness marker SOX2 showed a higher amplification prevalence in BCBM at 3.4% compared to 1.6%-0.96% in BC and 1.1%-1.15% in N-CNS for the 3 genes (Table 1).